Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial

Br J Anaesth. 2016 May;116(5):641-8. doi: 10.1093/bja/aew021.

Abstract

Background: Beneficial effects of tranexamic acid (TA) have been established in surgery and trauma. In ongoing postpartum haemorrhage (PPH), a moderate reduction of blood loss was observed in a previously published randomized controlled trial. Analysis of haemostasis parameters obtained from samples collected as part of this study are presented.

Methods: Women with PPH >800 ml after vaginal delivery were assigned to receive either TA (4 g over 1 h, then 1 g per h over six h) (TA) or not (H). A non-haemorrhagic group (NH), <800 ml blood loss, was included as postpartum reference. At four time-points (enrolment, +30 min, +2 h, +6 h), haemostasis was assessed. Haemostasis assays were performed blinded to group allocation. Data were expressed as median [interquartiles] and compared with non-parametric tests.

Results: In H compared with NH group, D-dimers increase (3730 ng ml(-1) [2468-8493] vs 2649 [2667-4375]; P=0.0001) and fibrinogen and factor II decrease were observed at enrolment and became maximal 2 h later. When comparing TA to H patients, the increase in Plasmin-Antiplasmin-complexes at +30 min (486 ng ml(-1) [340-1116] vs 674 [548-1640]; P=0.03) and D-dimers at +2 h (3888 ng ml(-1) [2688-6172] vs 7495 [4400-15772]; P=0.0001) was blunted. TA had no effect on fibrinogen decrease.

Conclusions: This study provides biological evidence of an early increase in D-dimers and plasmin-antiplasmin complexes associated with active post-partum haemorrhage and its attenuation by the early use of a clinically effective high dose of TA, opening the perspective of dose ranging studies to determinate the optimal dose and timing in this setting.

Clinical trial registration: ISRCTN09968140.

Keywords: fibrinogen; fibrinolysis; postpartum haemorrhage; tranexamic acid.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Antifibrinolytic Agents / pharmacology
  • Antifibrinolytic Agents / therapeutic use*
  • Blood Coagulation Factors / metabolism
  • Blood Specimen Collection / methods
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Hemostasis / drug effects*
  • Humans
  • Postpartum Hemorrhage / blood
  • Postpartum Hemorrhage / prevention & control*
  • Pregnancy
  • Single-Blind Method
  • Tranexamic Acid / pharmacology
  • Tranexamic Acid / therapeutic use*

Substances

  • Antifibrinolytic Agents
  • Blood Coagulation Factors
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Tranexamic Acid